These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9098659)

  • 1. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.
    Janknegt R; Steenhoek A
    Drugs; 1997 Apr; 53(4):550-62. PubMed ID: 9098659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.
    Alabbadi I; Crealey G; Scott M; Baird S; Trouton T; Mairs J; McElnay J
    Clin Drug Investig; 2006; 26(9):485-94. PubMed ID: 17163281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using health outcomes data to inform decision-making: formulary committee perspective.
    Janknegt R
    Pharmacoeconomics; 2001; 19 Suppl 2():49-52. PubMed ID: 11700789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors for the treatment of hypertension drug selection by means of the SOJA method.
    Edgar L; Hogg A; Scott M; Timoney M; Mc Elnay J; Mairs J; Janknegt R
    Rev Recent Clin Trials; 2011 Jan; 6(1):69-93. PubMed ID: 20868351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. System of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision making.
    Janknegt R; Scott M; Mairs J; Timoney M; McElnay J; Brenninkmeijer R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S5-14. PubMed ID: 17931079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypnotics. Drug selection by means of the System of Objectified Judgement Analysis (SOJA) method.
    Janknegt R; van der Kuy A; Declerck G; Idzikowski C
    Pharmacoeconomics; 1996 Aug; 10(2):152-63. PubMed ID: 10163418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.
    Janknegt R
    Pharmacoeconomics; 1994 Jul; 6(1):15-33. PubMed ID: 10147351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. InforMatrix: ADP antagonists in acute coronary syndromes.
    Janknegt R; Ruiters L; Ten Cate H
    Expert Opin Pharmacother; 2012 Feb; 13(3):357-85. PubMed ID: 22220778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of SOJA and InforMatrix in practice: interactive web and workshop tools.
    Brenninkmeijer R; Janknegt R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S49-55. PubMed ID: 17931078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptans in the treatment of migraine: drug selection by means of the SOJA method.
    Janknegt R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S15-30. PubMed ID: 17931075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Choice of antibiotics in uncomplicated cystitis; application of 'system of objectified judgement analysis' (SOJA) method].
    Janknegt R; van den Broek PJ; Kullberg BJ; Stobberingh E
    Ned Tijdschr Geneeskd; 1999 Dec; 143(49):2466-71. PubMed ID: 10608985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulary evaluation of third-generation cephalosporins using decision analysis.
    Cano SB; Fujita NK
    Am J Hosp Pharm; 1988 Mar; 45(3):566-9. PubMed ID: 3285673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary.
    Calvo MV; Fruns I; Domínguez-Gil A
    Am J Hosp Pharm; 1990 Sep; 47(9):2002-6. PubMed ID: 1977316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING.
    Roldán ÚB; Badia X; Marcos-Rodríguez JA; de la Cruz-Merino L; Gómez-González J; Melcón-de Dios A; Caraballo-Camacho MO; Cordero-Ramos J; Alvarado-Fernández MD; Galiana-Auchel JM; Calleja-Hernández MÁ
    Int J Technol Assess Health Care; 2018 Jan; 34(5):519-526. PubMed ID: 30348241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. InforMatrix as an alternative tool in rational and transparent drug-decision making.
    Brenninkmeijer R; Mairs J; Timoney M; Scott M; McElnay J; Janknegt R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S31-6. PubMed ID: 17931076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it the time to rethink clinical decision-making strategies? From a single clinical outcome evaluation to a Clinical Multi-criteria Decision Assessment (CMDA).
    Migliore A; Integlia D; Bizzi E; Piaggio T
    Med Hypotheses; 2015 Oct; 85(4):433-40. PubMed ID: 26190311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
    Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
    Front Public Health; 2020; 8():162. PubMed ID: 32457865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.